AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05924958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprolidone
Description: This study assessed the effect of eplerenone on circulating Treg cells in patients with chronic heart failure by detecting the level of aldosterone in venous blood and the activity of Treg cells and the level of inflammatory factors related to it after taking drugs.
Study NCT06299293 — intervention group
Intervention type: OTHER
Intervention: Facial Emotion Recognition Test
Description: In this test, the ability to detect and recognize facial expressions of fear or anger will be investigated.
Study NCT06611839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib,venetoclax,azacytidine,cytarabine
Description: phase I:Induction therapy：Ivosidenib 、Venetoclax、Cytarabine 、DNR or IDA~Dose climbing stage: adopt the 3 + 3 design principle, and the dose 0 group is set as follows~dose level 0: Ivosidenib 500mg d1-28 Venetoclax 100mg d-2，200mg d-1，400mg d1-7 Cytarabine 100mg/m2/d, d1-7 DNR 60mg/m2/d，d1-3 or IDA 12mg/m2/d，d1-3~dose level -1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-2，200mg d-1，400mg d1-7 Cytarabine 100mg/m2/d, d1-5 DNR 60mg/m2/d，d1-2 or IDA 12mg/m2/d，d1-2~dose level 1:Ivosidenib 500mg d1-28 Venetoclax 100mg d-3，200mg d-2，400mg d-1 800mg d1-7 Cytarabine 100mg/m2/d, d1-7 DNR 60mg/m2/d，d1-3 or IDA 12mg/m2/d，d1-3~Consolidation therapy intermediate-dose cytarabine regimen ： 3 courses~If IDH1 mutant residual disease was positive before consolidation chemotherapy, Ivosidenib was added;~Maintenance treatment:~Azacytidine、Venetoclax 、Ivosidenib： 6 courses~phase II: dose based on phase I results
Study NCT06675968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Suture
Description: A capsular closure will be performed, closure of the gluteus medius with a direct tendon and absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
Study NCT06675968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transosseus Suture
Description: A capsular closure will be performed, transosseous suture with a non-absorbable suture. Addittionally, the iliotibial band, subcutaneous and skin suture closure will be performed.
Study NCT06677008 — intervention group
Intervention type: DEVICE
Intervention: Disposable endoscopic linear cutter stapler
Description: Investigational devices of all the models of the staplers and its cartridge listed in Study Plan(Plan number: CAK-PMCF)
Study NCT06676215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IAA mix supplement
Description: The intervention is a daily IAA dose that provides x1.5 the estimated average requirement (EAR) for a healthy child. This IAA dose will be mixed to the complementary food and will be taken once daily for 4 weeks (28 days) by the child in the intervention group.
Study NCT06676215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary food comprised of rice and legumes
Description: Each study child will receive standard complementary food which he/she will take once daily for 4 weeks (28 days)
Study NCT06676852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary palliative care
Description: Enrolled patient participants will receive Sentinel prior to and during their hospitalization for HCT. Prior to HCT, a transplant clinician (nurse practitioner - NP) will conduct a focused PC visit to build rapport, manage expectations regarding HCT, review anticipated symptoms, and discuss illness coping strategies. During the HCT hospitalization, HCT physicians and advanced practice providers will incorporate PC domains into their routine care of patients undergoing HCT.
Study NCT06676527 — intervention group
Intervention type: OTHER
Intervention: Follow-up study of the treated cohort
Description: For those patients who have reached the end point of the study, survival data during treatment with vorolanib is obtained for retrospective analysis. The patients who are still on treatment with vorolanib are followed up closely and survival data is obtained for prospective analysis. After summarizing the results of retrospective and prospective studies, relevant efficacy and safety conclusions will be drawn.
Study NCT06677463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Studying the effect of virtual reality glasses on women during pregnancy, for the first time, it is also used to facilitate the birth process
Study NCT06676124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Piper crocatum Extract Cookie
Description: Participants in the intervention group will receive cookies containing a standardized 10% ethyl acetate extract of Piper crocatum, known for its antioxidant and anti-inflammatory properties. These cookies will be consumed twice daily for 12 weeks. The intervention aims to assess the effects of Piper crocatum on renal biomarkers, such as MMP-9 and NGAL, in diabetic patients with early renal dysfunction
Study NCT06676124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Participants in the placebo group will receive cookies that are identical in appearance, taste, and texture to the active Piper crocatum cookies but do not contain the Piper crocatum extract. These cookies will be consumed twice daily for 12 weeks, serving as a control to assess the effects of the active intervention on renal biomarkers associated with diabetic nephropathy.
Study NCT06676306 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study NCT06483308 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: Radiotherapy using 30Gy in 6 fractions (alternate days) over 12 days.
Study NCT06676696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue low dose calcineurin inhibitor (CNI)
Description: CNI dose (tacrolimus or cyclosporine) will be adjusted to maintain low tacrolimus or cyclosporine whole blood trough levels from month 3 to month 24 or End of Study
Study NCT06676696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitor withdrawal at 6 months
Description: CNI dose (tacrolimus or cyclosporine) will be reduced to one-half on month 3 visit and completely withdrawn on month 6 visit.
Study NCT05685316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COPLA® cartilage implant
Description: In the investigation, the subjects will receive COPLA® device during normal clinical practice for cartilage repair surgery of the knee with bone marrow stimulation.
Study NCT06184152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CEUS imaging
Description: Contrast-enhanced ultrasound (CEUS)
Study NCT06184152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: aMRI imaging
Description: contrast enhanced abbreviated MRI (AMRI)
Study NCT06648785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 oxaliplatin
Study NCT06648785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine
Description: oral fluoropyrimidine 1000mg/m2
Study NCT04717570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foldax TRIA Mitral Valve
Description: Mitral Valve Replacement
Study NCT06575725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV
Study NCT06575725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06575725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06575725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV
Study NCT06575725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06575725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06575725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT05157360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT
Description: hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
Study NCT05157360 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline solution
Study NCT05364697 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IoNIR Ridaforolimus-Eluting Coronary Stent System
Description: The IoNIR Ridaforolimus-Eluting Coronary Stent System is a sterile single-use device/drug combination product, comprised of a cobalt chromium (CoCr) alloy-based stent coated with a bioresorbable polymer mesh which is embedded with drug, mounted on a Rapid Exchange (RX) delivery system.
Study NCT05500690 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid Tablet
Description: 5 mg folic acid supplement
Study NCT05398289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-week duration of antibiotic therapy
Description: The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
Study NCT05398289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-week duration of antibiotic therapy
Description: The aim is to show non-inferiority of a 4-week duration of antibiotic therapy versus a standard 6-week duration according to international guidelines
Study NCT05265819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: Mediterranean diet participants participated in the Mediterranean diet intervention for 12 weak and received dietary training from professional nutritionists at the baseline visit and samples of a Mediterranean diet for three times during the trial.
Study NCT05265819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroid hormone replacement therapy
Description: thyroid hormone replacement therapy
Study NCT05064748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benvitimod
Description: Benvitimod cream, 1%, applied twice daily for 12 weeks after enrolment.
Study NCT05789472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Executive functions and reaction times of all participants will be measured.
Study NCT06499584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: near field recording of human auditory nerve activity during retro sigmoid approach with contact electrode
Description: During surgery using a retro-sigmoid approach in the cerebellopontine angle (microvascular decompression), near-field recording of human auditory nerve activity using a contact electrode is performed on patients with normal or impaired hearing threshold.~Each patient is explored preoperatively by hearing tests. During the surgery, stimuli are delivered.
Study NCT04199728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector
Description: Liraglutide will be provided using an injection pen provided by the manufacturer
Study NCT04199728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection pen
Study NCT06259409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regenn® Negative Pressure Therapy System
Description: Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
Study NCT06259409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena™ Incision Management System
Description: Controlled application of negative pressure (i.e., reduced atmospheric pressure or mild vacuum) to manage the wound environment.
Study NCT05604885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 60 mg
Description: AP1189 tablets for oral use
Study NCT05604885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 80 mg
Description: AP1189 tablets for oral use
Study NCT05604885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189, 100 mg
Description: AP1189 tablets for oral use
Study NCT05604885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets for oral use
Study NCT06300775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified hyrax
Description: Appliance used for rapid maxillary expansion
Study NCT06300775 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: quad helix
Description: device use for slow maxillary expansion
Study NCT06315777 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cumulus cell oocytes complex (COC) among women with poor ovarian reserve
Description: level of expression of Gremlin-1 (GREM1), Hyaluronic acid synthetase-2 (HAS2), and Prostaglandin-endoperoxide synthase-2 (PTGS2) in cumulus cell oocytes complex (COC) among women with poor ovarian reserve were analyzed
Study NCT04788836 — intervention group
Intervention type: OTHER
Intervention: Questionnaire (Survey and Food Frequency Questionnaire (FFQ))
Description: Each participant will be asked to fill a web-based questionnaire that captures sociodemographic, lifestyle, physical and mental health information (Survey) and dietary intake patterns (FFQ). This will be done pre-treatment (only for those included pre-treatment), 6 months after the start of obesity treatment, 1 year after the start of the treatment and then yearly until 5 year after the start of the treatment.
Study NCT04788836 — intervention group
Intervention type: OTHER
Intervention: Collection of digital receipts from grocery shopping
Description: Participants will create their BitsaboutMe-account (GDPR-compliant data sharing platform from Bern, Switzerland) with the help of study team members. Data from digital receipts will be obtained from Migros Cumulus and Coop Supercard via their BitsaboutMe-account. The data collection allow retrospective digital receipts collection for up to 2 years and automatically continuous collection during study duration.~GDPR: General Data Protection Regulation
Study NCT05574881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: 150 mg qd
Study NCT05574881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg d1, 15, 29, and then q4w
Study NCT05765695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation performed with a 19 gauge STARmed needle.
Description: The ablation with radiofrequency is a safe and effective minimally invasive procedure that results in thermal tissue necrosis. A needle electrode is inserted into the thyroid nodule using ultrasound guidance and generates heat by alternating electric current causing thermal injury. Afterwards, the ablated tissue is gradually absorbed with progressive shrinkage of the nodule.
Study NCT06016920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenous (i.v.) will be given in accordance with the local regulatory-approved label Q3W starting at Week 1/Day 1 for as long as the patient tolerates and continues to have clinical benefit from the treatment based on the patient and investigator's decision, up to a maximum of 35 treatments corresponding to approximately 2 years of treatment.~After 48 weeks of treatment patients can continue on 200 mg Q3W or change to 400 mg Q6W at the discretion of the investigator and after consultation with the sponsor.~Pembrolizumab will be given by i.v. infusion over 30 minutes.
Study NCT05825209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Food-Grown Magnesium
Description: 1 daily dose of 2 capsules equivalent to 80mg food-grown magnesium (40mg per capsule)
Study NCT05825209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: 1 daily dose of 2 capsules containing microcrystalline cellulose
Study NCT05360420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immediate CEUS
Description: Subjects will receive CEUS examination immediately for the suspicious lesion detected by US.
Study NCT05574881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840mg q3w, and then 420 mg q3w
Study NCT05574881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg q3w, and then 6 mg/kg q3w
Study NCT06347991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SelfBack
Description: The SelfBack app is a promising decision support system (DSS) App used globally to support and reinforce desired self-management behavior for LBP. Selfback's program goal is to improve the self-management of nonspecific LBP to reduce pain-related disability.
Study NCT04905199 — intervention group
Intervention type: PROCEDURE
Intervention: Temporary transvenous cardiac pacing
Description: Transvenous temporary pacemaker insertion by modified IC-ECG monitoring.
Study NCT05966844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfluness and Virtual Reality
Description: They will undergo six mindfulness sessions in virtual reality for about six weeks. One session per week of approximately 5-10 minutes.
Study NCT04755712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rachianesthesia
Description: Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
Study NCT04755712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rachianesthesia
Description: Administration of different anesthesia drugs in accordance with the courant practice (mixture of bupivacaine and sufentanil)
Study NCT04755712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride Injection
Description: Subcutaneous injection of Sodium chloride at the usual quadratum lumburum block 2 (QLB2) injection site under ultrasound (sham-QLB2).
Study NCT04755712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine via pump (patient controlled analgesia)
Study NCT04755712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine via pump (patient controlled analgesia)
Study NCT06302972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: Hot Pack will be applied at the beginning of the session for 10 minutes. Wall corner stretching exercises, neck isometric exercises and neck stretching exercises will be performed Cold pack will be applied at the end of the session for a few minutes.
Study NCT06302972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM and CCEP
Description: Instrument Assisted Soft Mobilization Technique (IASTM); For pectoralis major:~Subjects will be asked to lay supine with their thorax front side exposed. In abduction, restriction or adhesions will be located using scanning and gel will be applied. IASTM also address soft tissue restrictions and pain in levator scapulae, suboccipital muscles and sternocleidomastoid muscle.~The Comprehensive Corrective Exercise Program (CCEP) will be designed in three phases, including initial, improvement, and maintenance.. The exercises in appropriate muscles in correct alignment during the movement pattern, the protocol focused on improving sustained postures.~Exercises in initial phase protocol from 10 s hold x7 to 15 s hold x 10 from roller Exercises in improvement phase protocol from 10 repetition x 5 to 15 repetition x 6 from dumbbell , thera band, swiss ball and balance board
Study NCT04714593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
Study NCT05278650 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Senior PharmAssist^TM Program Implementation
Description: Representatives from three diverse communities will participate in co-design workshops to refine the Senior PharmAssistTM (SPA) implementation toolkit, which will then be delivered to agency staff from these partnering communities through a series of learning collaborative sessions to facilitate implementation of SPA core components in each community.~Community champions will be trained to deliver a community-based program to deliver the core components of SPA:~1. Medication Therapy Management (MTM);~2. Medication co-payment assistance;~3. Tailored community referrals; and~4. Medicare insurance counseling
Study NCT04811469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBP-174
Description: CBP-174 oral solution, given once
Study NCT04811469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution, given once
Study NCT05235217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product (T) 40 mg Hard Gelatin Capsules
Description: Hard Gelatin Capsules products containing 40 mg Esomeprazole
Study NCT05235217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product (R) 40 mg Hard Gelatin Capsules
Description: Reference product (R) 40 mg Hard Gelatin Capsules
Study NCT06186752 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyIBD
Description: MyIBD has two components: (1) an electronic, templated document that presents brief, actionable, tailored guidance from IBD specialists to families and other providers who care for a pediatric patient with IBD; and (2) regular, short prompts sent through the electronic patient portal to remind patients to refer to and use their MyIBD document to guide decisions about care in between appointments.
Study NCT06082752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage session
Description: Participants in the intervention group are provided with the 5-minute massage session in the medial and lateral gastrocnemius muscle (dominant leg).